210 related articles for article (PubMed ID: 28595297)
1. FGFR2 mutations in bent bone dysplasia syndrome activate nucleolar stress and perturb cell fate determination.
Neben CL; Tuzon CT; Mao X; Lay FD; Merrill AE
Hum Mol Genet; 2017 Sep; 26(17):3253-3270. PubMed ID: 28595297
[TBL] [Abstract][Full Text] [Related]
2. Bent bone dysplasia syndrome reveals nucleolar activity for FGFR2 in ribosomal DNA transcription.
Neben CL; Idoni B; Salva JE; Tuzon CT; Rice JC; Krakow D; Merrill AE
Hum Mol Genet; 2014 Nov; 23(21):5659-71. PubMed ID: 24908667
[TBL] [Abstract][Full Text] [Related]
3. Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has deficient canonical FGF signaling.
Merrill AE; Sarukhanov A; Krejci P; Idoni B; Camacho N; Estrada KD; Lyons KM; Deixler H; Robinson H; Chitayat D; Curry CJ; Lachman RS; Wilcox WR; Krakow D
Am J Hum Genet; 2012 Mar; 90(3):550-7. PubMed ID: 22387015
[TBL] [Abstract][Full Text] [Related]
4. Nuclear FGFR2 regulates musculoskeletal integration within the developing limb.
Salva JE; Roberts RR; Stucky TS; Merrill AE
Dev Dyn; 2019 Mar; 248(3):233-246. PubMed ID: 30620790
[TBL] [Abstract][Full Text] [Related]
5. Dura in the pathogenesis of syndromic craniosynostosis: fibroblast growth factor receptor 2 mutations in dural cells promote osteogenic proliferation and differentiation of osteoblasts.
Ang BU; Spivak RM; Nah HD; Kirschner RE
J Craniofac Surg; 2010 Mar; 21(2):462-7. PubMed ID: 20489451
[TBL] [Abstract][Full Text] [Related]
6. FGFR and PTEN signaling interact during lens development to regulate cell survival.
Chaffee BR; Hoang TV; Leonard MR; Bruney DG; Wagner BD; Dowd JR; Leone G; Ostrowski MC; Robinson ML
Dev Biol; 2016 Feb; 410(2):150-163. PubMed ID: 26764128
[TBL] [Abstract][Full Text] [Related]
7. Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts.
Suzuki H; Suda N; Shiga M; Kobayashi Y; Nakamura M; Iseki S; Moriyama K
J Cell Physiol; 2012 Sep; 227(9):3267-77. PubMed ID: 22105374
[TBL] [Abstract][Full Text] [Related]
8. Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation.
Mansukhani A; Ambrosetti D; Holmes G; Cornivelli L; Basilico C
J Cell Biol; 2005 Mar; 168(7):1065-76. PubMed ID: 15781477
[TBL] [Abstract][Full Text] [Related]
9. Effects of FGFR Signaling on Cell Proliferation and Differentiation of Apert Dental Cells.
Lu C; Huguley S; Cui C; Cabaniss LB; Waite PD; Sarver DM; Mamaeva OA; MacDougall M
Cells Tissues Organs; 2016; 201(1):26-37. PubMed ID: 26613250
[TBL] [Abstract][Full Text] [Related]
10. Activating (P253R, C278F) and dominant negative mutations of FGFR2: differential effects on calvarial bone cell proliferation, differentiation, and mineralization.
Ratisoontorn C; Fan GF; McEntee K; Nah HD
Connect Tissue Res; 2003; 44 Suppl 1():292-7. PubMed ID: 12952211
[TBL] [Abstract][Full Text] [Related]
11. Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways.
Raucci A; Bellosta P; Grassi R; Basilico C; Mansukhani A
J Cell Physiol; 2008 May; 215(2):442-51. PubMed ID: 17960591
[TBL] [Abstract][Full Text] [Related]
12. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.
Lengner CJ; Steinman HA; Gagnon J; Smith TW; Henderson JE; Kream BE; Stein GS; Lian JB; Jones SN
J Cell Biol; 2006 Mar; 172(6):909-21. PubMed ID: 16533949
[TBL] [Abstract][Full Text] [Related]
13. The roles of RRP15 in nucleolar formation, ribosome biogenesis and checkpoint control in human cells.
Dong Z; Zhu C; Zhan Q; Jiang W
Oncotarget; 2017 Feb; 8(8):13240-13252. PubMed ID: 28099941
[TBL] [Abstract][Full Text] [Related]
14. A role for fibroblast growth factor receptor-2 in the altered osteoblast phenotype induced by Twist haploinsufficiency in the Saethre-Chotzen syndrome.
Guenou H; Kaabeche K; Mée SL; Marie PJ
Hum Mol Genet; 2005 Jun; 14(11):1429-39. PubMed ID: 15829502
[TBL] [Abstract][Full Text] [Related]
15. Inducible Activation of FGFR2 in Adult Mice Promotes Bone Formation After Bone Marrow Ablation.
Xu W; Luo F; Wang Q; Tan Q; Huang J; Zhou S; Wang Z; Sun X; Kuang L; Jin M; Su N; Jiang W; Chen L; Qi H; Zhu Y; Chen B; Chen H; Chen S; Gao Y; Xu X; Deng C; Chen L; Xie Y; Du X
J Bone Miner Res; 2017 Nov; 32(11):2194-2206. PubMed ID: 28650109
[TBL] [Abstract][Full Text] [Related]
16. The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects.
Ota S; Zhou ZQ; Link JM; Hurlin PJ
Hum Mol Genet; 2009 Jul; 18(14):2609-21. PubMed ID: 19403560
[TBL] [Abstract][Full Text] [Related]
17. FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt signaling and osteoblast survival.
Dufour C; Guenou H; Kaabeche K; Bouvard D; Sanjay A; Marie PJ
Bone; 2008 Jun; 42(6):1032-9. PubMed ID: 18374639
[TBL] [Abstract][Full Text] [Related]
18. Perturbation of ribosome biogenesis drives cells into senescence through 5S RNP-mediated p53 activation.
Nishimura K; Kumazawa T; Kuroda T; Katagiri N; Tsuchiya M; Goto N; Furumai R; Murayama A; Yanagisawa J; Kimura K
Cell Rep; 2015 Mar; 10(8):1310-23. PubMed ID: 25732822
[TBL] [Abstract][Full Text] [Related]
19. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis.
Bursac S; Brdovcak MC; Donati G; Volarevic S
Biochim Biophys Acta; 2014 Jun; 1842(6):817-30. PubMed ID: 24514102
[TBL] [Abstract][Full Text] [Related]
20. Non-genotoxic activation of p53 through the RPL11-dependent ribosomal stress pathway.
Morgado-Palacin L; Llanos S; Urbano-Cuadrado M; Blanco-Aparicio C; Megias D; Pastor J; Serrano M
Carcinogenesis; 2014 Dec; 35(12):2822-30. PubMed ID: 25344835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
